NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: ABVC BioPharma's Plant-Based ADHD Candidate and Psychiatric Polypharmacy Concerns
TL;DR
ABVC BioPharma's plant-based ADHD drug ABV-1505 offers a competitive edge with its non-addictive, non-stimulant profile that may reduce long-term medication burden compared to conventional treatments.
ABV-1505 is a botanical extract from Polygala tenuifolia that works as a non-stimulant ADHD treatment, showing efficacy in Phase II trials with no serious adverse events reported.
ABVC's plant-based ADHD candidate ABV-1505 could make tomorrow better by providing safer treatment options that reduce the need for multiple psychiatric medications over a patient's lifetime.
ABVC BioPharma is developing a plant-based ADHD drug from Polygala tenuifolia that shows promise as a non-addictive alternative to traditional stimulant medications.
Found this article helpful?
Share it with your network and spread the knowledge!
ABVC BioPharma is addressing concerns about psychiatric polypharmacy in ADHD treatment by highlighting the safety-focused approach of its plant-based drug candidate ABV-1505, which has shown favorable tolerability in early clinical studies.
Psychiatric polypharmacy refers to the use of multiple psychiatric medications over time, and it's concerning because media reports and analyses suggest children and adolescents starting ADHD medications are more likely than the general population to later receive additional psychiatric drug prescriptions.
The Wall Street Journal has highlighted this growing concern, referencing anecdotal accounts from individuals who began ADHD medication at a young age and ultimately received numerous additional psychiatric drug prescriptions over time.
ABV-1505 is a botanical extract derived from Polygala tenuifolia that is plant-based, non-stimulant, not shown to cause addiction or dependency, and designed to potentially reduce the likelihood of escalating to multi-drug psychiatric regimens.
ABV-1505 has demonstrated a favorable tolerability profile in early clinical in-house studies with no drug-related serious adverse events reported to date, and a Phase II trial at UCSF showed it was well tolerated with no serious safety concerns observed.
ABV-1505 completed a Phase II clinical trial at the University of California, San Francisco (UCSF) that showed statistically significant improvement on ADHD rating scales compared with placebo.
Children and adolescents with ADHD who begin medication treatment are affected, as they appear more likely to receive additional psychiatric drug prescriptions over time compared to the general population.
This announcement addresses public concerns about long-term medication burden associated with conventional ADHD therapies and positions ABV-1505 as a potential safer alternative that could minimize downstream medication requirements.
The Wall Street Journal article can be accessed at https://www.wsj.com/tech/personal-tech/when-adhd-meds-are-just-the-start-70a61ca7.
More information about ABVC BioPharma can be found on their website at http://abvcpharma.com/.
Curated from NewMediaWire
